Skip to main content

Advertisement

SpringerLink
Log in

Management of Hepatitis C Virus—Genotypes 4, 5, and 6 Using Direct Antiviral Agents: Review of Current Status

  • Hepatitis C (K Marks, Section Editor)
  • Published:
Current Treatment Options in Infectious Diseases Aims and scope Submit manuscript

Opinion Statement

A small number of studies were done on Hepatitis C virus genotypes 4, 5, and 6; that is why limited data were available on the most effective management for these patients. In the past, treatment of this kind of patients depended on the use of the suboptimal regimen of interferon with ribavirin achieving moderate efficacy with numerous side effects. However, with the introduction of the new directly acting antiviral drugs (DAAs), multiple agents became available for treatment showing high success rates, excellent tolerability, and few adverse events.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Heading

Papers of particular interest, published recently, have been highlighted as: • Of importance

  1. Frank C, Mohamed MK, Strickland GT, et al. The role of parenteral antischistosomal therapy in the spread of hepatitis C virus in Egypt. Lancet. 2000;355(9207):887–91.

    Article  CAS  PubMed  Google Scholar 

  2. Sterling RK, Bralow S. Extrahepatic manifestations of hepatitis C virus. Curr Gastroenterol Rep. 2006;8(1):53–9.

    Article  PubMed  Google Scholar 

  3. Bonkovsky HL, Mehta S. Hepatitis C: a review and update. J Am Acad Dermatol. 2001;44(2):159–82.

    Article  CAS  PubMed  Google Scholar 

  4. NIH Consens State Sci Statements. 2002; 19(3):1–46.

  5. Robertson B, Myers G, Howard C, Brettin T, Bukh J, Gaschen B, et al. Classification, nomenclature, and database development for hepatitis Cvirus (HCV) and related viruses: proposals for standardization. International Committee on Virus Taxonomy. Arch Virol. 1998;143:2493–503.

    Article  CAS  PubMed  Google Scholar 

  6. Hnatyszyn HJ. Chronic hepatitis C and genotyping: the clinical significance of determining HCV genotypes. Antiviral Ther. 2005;10:1–11.

    CAS  Google Scholar 

  7. Arase Y, Kobayashi M, Suzuki F, Suzuki Y, Kawamura Y, Akuta N, et al. Effect of type 2 diabetes on risk for malignancies includes hepatocellular carcinoma in chronic hepatitis C. Hepatology. 2013;57:964–73.

    Article  CAS  PubMed  Google Scholar 

  8. Van der Meer AJ, Veldt BJ, Feld JJ, Wedemeyer H, Dufour JF, Lammert F, et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA. 2012;308:2584–93.

    Article  PubMed  Google Scholar 

  9. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol. 2011;55:245–64.

    Article  Google Scholar 

  10. Antaki N, Craxi A, Kamal S, Moucari R, Van der Merwe S, Haffar S, et al. The neglected hepatitis C virus genotypes 4, 5, and 6: an international consensus report. Liver Int. 2010;30:342–55.

    Article  CAS  PubMed  Google Scholar 

  11. Poordad F, Dieterich D. Treating hepatitis C: current standard of care and emerging direct-acting antiviral agents. J Viral Hepat. 2012;19:449.

    Article  CAS  PubMed  Google Scholar 

  12. Nguyen MH, Keeffe EB. Prevalence and treatment of hepatitis C virus genotypes 4, 5, and 6. Clin Gastroenterol Hepatol. 2005;3 Suppl 2:S97–101.

    Article  CAS  PubMed  Google Scholar 

  13. Abdel-Razek W, Waked I. Optimal therapy in genotype 4 chronic hepatitis C: finally cured? Liver Int. 2015;35 Suppl 1:27–34.

    Article  CAS  PubMed  Google Scholar 

  14. Gentile I, Borgia F, Buonomo AR, et al. A novel promising therapeutic option against hepatitis C virus: an oral nucleotide NS5B polymerase inhibitor sofosbuvir. Current Med Chem. 2013;20:3733–42.

    Article  CAS  Google Scholar 

  15. Hassanein T, Lawitz E, Crespo I, Davis M, DeMicco MP, Nelson DR. Once daily sofosbuvir (GS-7977) plus PEG/RBV: high early response rates are maintained during post-treatment follow-up in treatment-naive patients with HCV genotype 1, 4, and 6 infection in the ATOMIC study. Hepatology. 2012;56:307A.

    Google Scholar 

  16. Rodriguez-Torres M, Lawitz E, Kowdley KV, Nelson DR, Dejesus E, McHutchison JG. Sofosbuvir (GS-7977) plus peginterferon/ribavirin in treatment-naïve patients with HCV genotype 1: a randomized, 28-day, dose-ranging trial. J Hepatol. 2013;58:663–8.

    Article  CAS  PubMed  Google Scholar 

  17. Mathias A, Cornpropst M, Clemons D, Denning J, Symonds WT. No clinically significant pharmacokinetic drug–drug interactions between sofosbuvir (GS-7977) and the immunosuppressants, cyclosporine a or tacrolimus in healthy volunteers. Hepatology. 2012;56:1063A–4.

    Google Scholar 

  18. Murakami E, Tolstykh T, Bao H, Niu C, Steuer HM, Bao D, et al. Mechanism of activation of PSI-7851 and its diastereoisomer PSI-7977. J Biol Chem. 2010;285(45):34337–47.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Lawitz E, Freilich B, Link J, et al. A phase 1, randomized, dose-ranging study of GS-5816, a once-daily NS5A inhibitor, in patients with genotype 1–4 hepatitis C virus. J Viral Hepat. 2015;22:1011–9.

    Article  CAS  PubMed  Google Scholar 

  20. Feld JJ, Jacobson IM, Hézode C, et al. Sofosbuvir and velpatasvir for HCV genotype 1, 2, 4, 5, and 6 infection. N Engl J Med. 2015;373(27):2599–607.

    Article  CAS  PubMed  Google Scholar 

  21. J Hepatol. 2015; 63:j 199–236

  22. Abergel A, Asselah T, Metivier S, Kersey K, Jiang D, Mo H, et al. Ledipasvir-sofosbuvir in patients with hepatitis C virus genotype 5 infection: an open-label, multicentre, single-arm, phase 2 study. Lancet Infect Dis. 2016;16(4):459–64. doi:10.1016/S1473-3099(15)00529-0.

    Article  CAS  PubMed  Google Scholar 

  23. Kohli A, Kapoor R, Sims Z, et al. Ledipasvir and sofosbuvir for hepatitis C genotype 4: a proof-of-concept, single-centre, open-label phase 2a cohort study. Lancet Infect Dis. 2015;15(9):1049–54.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Charlton M, Everson GT, Flamm SL, et al. Ledipasvir and sofosbuvir plus ribavirin for treatment of HCV infection in patients with advanced liver disease. Gastroenterology. 2015;149(3):649–59 (Limited regimens are available for patients with decompensated liver disease, results of this study showed high efficacy for the use of Sofosbuvir/Ledipasvir in this type of patients.).

    Article  CAS  PubMed  Google Scholar 

  25. Poordad F et al. Daclatasvir with sofosbuvir and ribavirin for hepatitis C virus infection with advanced cirrhosis or post-liver transplantation recurrence. Hepatology. 2016;63(5):1493–505. doi:10.1002/hep.28446.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. V. De Ledinghen, et al. Safety and efficacy of sofosbuvir-containing regimens in the French observational cohort ANRS CO22 HEPATHER. 2015; 62:631–2

  27. Lawitz E, Sulkowski MS, Ghalib R, Rodriguez-Torres M, Younossi ZM, Corregidor A, et al. Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study. Lancet. 2014;384:1756–65.

    Article  CAS  PubMed  Google Scholar 

  28. El-Khayat HR, Fouad YM, Maher M, El-Amin H, Muhammed H. Efficacy and safety of sofosbuvir plus simeprevir therapy in Egyptian patients with chronic hepatitis C: a real-world experience. Gut. 2016. doi:10.1136/gutjnl-2016-312012. Sofosbuvir/Simeprevir, despite still being not FDA approved for genotype 4, results shown hold promising success rate.

  29. Hanno A, Elwazzan D, Ibrahim M, Hafez R. A real life study on treatment of Egyptian patients with HCV genotype IV with simeprevir and sofosbuvir. Health. 2016;8:780–6. Sofosbuvir/Simeprevir, despite still being not FDA approved for genotype 4, results shown hold promising success rate.

  30. Carrion AF, Gutierrez J, Martin P. New antiviral agents for the treatment of hepatitis C:ABT-450. Expert Opin Pharmacother. 2014;15:711–6.

    Article  CAS  PubMed  Google Scholar 

  31. Hezode C, Asselah T, Reddy KR, Hassanein T, Berenguer M, Fleischer-Stepniewska K, Marcellin P, et al. Ombitasvir plus paritaprevir plus ritonavir with or without ribavirin in treatment-naive and treatment-experienced patients with genotype 4 chronic hepatitis C virus infection (PEARL-I): a randomised, open-label trial. Lancet 2015.

  32. Asselah T, Hassanien T, Qaqish RB, et al. P1345: A randomized, open-label study to evaluate efficacy and safety of ombitasvir/paritaprevir/ritonavir co-administered with ribavirin in adults with genotype 4 chronic hepatitis C infection and cirrhosis. Journal of Hepatology. 2015;62:S861.

    Article  Google Scholar 

  33. Esmat GE, Shiha G, et al. Ombitasvir, paritaprevir and ritonavir plus ribavirin for chronic hepatitis C virus genotype 4 infection in Egyptian patients with or withour compensated cirrhosis (AGATE-II) a multicentre, phase 3, partly randomized open-label trial. The Lancet. 2016;1(1):36–44.

    Google Scholar 

  34. Keating GM. Elbasvir/grazoprevir: first global approval. Drugs. 2016;76(5):617–24. doi:10.1007/s40265-016-0558-3.

    Article  CAS  PubMed  Google Scholar 

  35. Asselah T, Hendrick W, Reesink, et al. High efficacy of elbasvir and grazoprevir with or without ribavirin in 103 treatment-naïve and experienced patients with HCV genotype 4 infection: a pooled analysis. 66th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD). 2015; San Francisco, CA

  36. Zeuzem S, Ghalib R, Reddy KR, Pockros PJ, Ari ZB, Zhao Y, et al. Grazoprevir-elbasvir combination therapy for treatment-naive cirrhotic and noncirrhotic patients with chronic hepatitis C virus genotype 1, 4, or 6 infection: a randomized trial. Ann Intern Med. 2015;163(1):1–13. doi:10.7326/M15-0785.

    Article  PubMed  Google Scholar 

  37. Smuts HE, Kannemeyer J. Genotyping of hepatitis C virus in South Africa. J Clin Microbiol. 1995;33:1679–81.

    CAS  PubMed  PubMed Central  Google Scholar 

  38. Mellor J, Walsh EA, Prescott LE, Jarvis LM, Davidson F, Yap PL, et al. Survey of type 6 group variants of hepatitis C virus in Southeast Asia by using a core-based genotyping assay. J Clin Microbiol. 1996;34(2):417–23.

    CAS  PubMed  PubMed Central  Google Scholar 

  39. Wong KA, Worth A, Martin R, et al. Characterization of hepatitis C virus resistance from a multiple-dose clinical trial of the novel NS5A inhibitor GS-5885. Antimicrob Agents Chemother. 2013;57(12):6333–40.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  40. Kohler JJ, Nettles JH, Amblard F, et al. Approaches to hepatitis C treatment and cure using NS5A inhibitors. Infect Drug Resist. 2014;7:41–56.

    PubMed  PubMed Central  Google Scholar 

  41. Hyland RH, An D, Svarovskaia E, Pang PS, Brainard D, Stedman CA. Efficacy of ledipasvir and sofosbuvir, with or without ribavirin, for 12 weeks in patients with HCV genotype 3 or 6 infection. 2015;149:1454–61.

  42. Brown A, Hezode C, Zuckerman E et al. C-SCAPE: Efficacy and safety of 12 weeks of grazoprevir +/− elbasvir +/_ ribavirin in patients with HCV GT2, 4, 5 or 6 infection [Abstract #P0771]. 50th Annual Meeting of the European Association for the Study of the Liver (EASL). April 22–26, 2015; Vienna, Austria.

  43. G Esmat, M El Raziky, A Gomaa, et al. High virologic response rate in Egyptian HCV-geno- type 4 patients treated with ravidasvir (PPI-668) and sofosbuvir: results of a large multicenter phase 3 registrational trial. AASLD Liver Meeting. San Francisco, November 13–17, 2015. Abstract LB-4.

Download references

Author information

Authors and Affiliations

  1. Endemic Medicine and Hepatogastroenterology Department, Faculty of Medicine, Cairo University, 42 street 108, Hadaek el Maadi, Cairo, Egypt

    Mohamed B. Hashem MSc, Tamer Elbaz MD & Gamal Esmat MD

  2. Hepatology Department, National Hepatology and Tropical Medicine Research Institute, Cairo, Egypt

    Mohamed El-kassas MD

Authors
  1. Mohamed B. Hashem MSc
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Tamer Elbaz MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Mohamed El-kassas MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Gamal Esmat MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mohamed B. Hashem MSc.

Ethics declarations

Conflict of Interest

Dr. Mohamed B. Hashem, Dr. Tamer Elbaz, Dr. Mohamed El-kassas, and Dr. Gamal Esmat declare that they have no conflict of interest.

Human and Animal Rights and Informed Consent

With regard to the authors’ research cited in this paper, all procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. In addition, all applicable international, national, and/or institutional guidelines for the care and use of animals were followed.

Additional information

This article is part of the Topical Collection on Hepatitis C

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Hashem, M.B., Elbaz, T., El-kassas, M. et al. Management of Hepatitis C Virus—Genotypes 4, 5, and 6 Using Direct Antiviral Agents: Review of Current Status. Curr Treat Options Infect Dis 8, 368–378 (2016). https://doi.org/10.1007/s40506-016-0094-4

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40506-016-0094-4

Keywords

Search

Navigation